What Is Combination Therapy for Lung Cancer?

Combination therapy is essentially a one-two punch at cancer—sometimes with multiple punches. For people with lung cancer, it means treating a tumor with more than one type of therapy at the same time or in sequence, often because those treatments work better together than alone.

The idea is straightforward: If cancer cells develop resistance to one drug, another treatment that works in a different way may continue attacking the tumor.

“Cancer is smart,” says Sarah Goldberg, MD, MPH, Yale Medicine’s chief of thoracic oncology. “If you try to hit it from only one angle, it can figure out what you’re doing and start to grow using other pathways. But hitting it from different directions might be more successful. That's what we've been seeing.”

Combination therapies are not used for every type of lung cancer. But they have become an increasingly important focus as doctors expand the use of targeted therapies, immunotherapies, and chemotherapy—and tailor those treatments to each patient’s tumor biology.

Research shows that combination approaches can help some patients keep lung cancer under control longer and, in certain cases, live longer.

A major challenge in lung cancer treatment is treatment resistance—when cancer adapts or evolves and stops responding to a therapy.

“Cancer is so insidious, and it just has so much ability to change and spread,” says Yale Medicine’s Roy Herbst, MD, PhD, chief of medical oncology and hematology, deputy director for Yale Cancer Center and Smilow Cancer Hospital, and a pioneer in lung cancer research.

For decades, doctors have combined treatments. Traditionally, that meant chemotherapy plus surgery or radiation, depending on the type and stage of cancer.

More recently, newer therapies have expanded those combinations:

• Targeted therapy, which blocks specific genetic changes driving tumor growth
• Immunotherapy, which helps the body’s immune system recognize and attack cancer
• Chemotherapy, which kills rapidly dividing cells

The goal is to use therapies with different mechanisms of action to reduce the chance that cancer will outmaneuver treatment.

Some combinations are now standard of care. Others are being tested in clinical trials.

Precision medicine has sharpened the focus on combination therapy. Instead of a one-size-fits-all approach, treatment is increasingly tailored to the biological features of each person’s tumor.

That process begins with a biopsy. A pathologist first determines whether the cancer is small cell lung cancer (SCLC) or non-small cell lung cancer (NSCLC), which is more common. NSCLC includes several subtypes, such as adenocarcinoma, the most common form.

For many people with NSCLC, the next step is extensive molecular testing. Doctors look for “driver mutations”—specific genetic changes that fuel tumor growth.

“We look at the genes, the DNA of the cancer, and what drives the cancer to grow,” Dr. Goldberg says. “There are many possible genetic alterations that could be telling the cells to grow abnormally, to change and spread, which wouldn’t happen in normal cells.”

That information helps determine whether targeted therapy alone—or in combination with chemotherapy or another drug—may be appropriate.

“We personalize treatment based on that information, and on other medical issues they might have and their wishes as far as treatment,” Dr. Goldberg says.

Some patients with advanced cancer who are frail from other health conditions may prioritize treatments that extend life as long as possible. Others may focus more on maintaining quality of life.

“Everyone is different,” she says.

One of the most significant recent advances involves non-small cell lung cancer with a mutation in the epidermal growth factor receptor (EGFR) gene.

EGFR-mutated NSCLC is driven by a change in this gene that affects how cells grow and divide. For years, it was treated with a single targeted therapy pill called osimertinib, which replaced chemotherapy for many patients. More recently, clinical trials have shown that certain combinations may improve outcomes—although they can also increase side effects.

In the FLAURA2 clinical trial, researchers studied people with advanced EGFR-mutated NSCLC. They found that combining the targeted drug osimertinib with the chemotherapies carboplatin and pemetrexed helped patients live longer compared with those who received osimertinib alone. The Food and Drug Administration approved this combination in 2024. In another trial, the MARIPOSA trial, amivantamab plus lazertinib (two drugs that block EGFR in different ways) also improve survival compared to osimertinib alone.

In a January 2026 editorial in the New England Journal of Medicine, Dr. Herbst wrote that such results “may signal the need for a shift in treatment philosophy, suggesting that earlier, more aggressive intervention might offer more durable responses and better outcomes.” He says, “We will move our best therapies to earlier stages of disease—this is how we will work to cure lung cancer.”

At the same time, he noted that important questions remain: Which patients benefit most? Could earlier, more intensive therapy delay resistance? And does starting with combination therapy change long-term outcomes?

“We are still learning all the time—this is why clinical trials are so important,” Dr. Herbst says.

Side effects are an important part of treatment decisions.

“For EGFR-mutated NSCLC, we now have two options for combination therapy and the side effects are very different,” Dr. Goldberg says. For example, a regimen that includes chemotherapy may cause fatigue and nausea. Or a combination of targeted therapies may cause rash, diarrhea, or nail changes.

While side effects can be challenging, they can often be managed with supportive medications, dose adjustments, or short breaks from treatment. “Sometimes people need what we call a ‘treatment holiday,’ where we give them a break,” Dr. Goldberg says. Still, combination therapy may increase the likelihood of side effects compared to a single drug.

“Sometimes the side effect profile helps us decide what treatment is better for someone,” she says. “For instance, one person might want to keep working during their treatment, so they might prefer to avoid fatigue.”

Because treatment plans are increasingly personalized, patients may have options. Dr. Goldberg suggests asking:

• Why is this particular combination recommended for my cancer?
• How will we know if it’s working?
• What side effects are most likely?
• How might treatment affect my daily life?
• Are there clinical trials I should consider?

“It’s dependent on what you want and what’s important to you, and you want to make your opinion about that heard,” she says.

Research continues to explore which drug combinations work best—and for whom.

“The progress has been amazing,” Dr. Herbst says. “But I would love it if someday we could take any individual’s tumor and say, ‘You need A and B plus C.’ We need to understand what are the cancer’s vulnerabilities so we can target it with the best medication, and what are the resistance pathways.”

In the meantime, he emphasizes the importance of lung cancer screening for eligible individuals, which can often find lung cancer at an early stage when the disease has the best chance of being cured.

“If we can use these drugs before the tumor is at an advanced stage, we have a better shot of killing the tumor and heading off resistance,” he says.